Scientists test new hope pill to fight devastating nerve disease
NCT ID NCT04562831
Summary
This study is testing whether a combination of two dietary supplements, Nicotinamide Riboside and Pterostilbene, can slow down the progression of ALS (Lou Gehrig's disease). The trial involves 380 people with ALS who will take either the supplement or a placebo. Researchers aim to see if this treatment can delay disability, improve quality of life, and potentially increase survival time for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Akershus University Hospital
Lørenskog, Norway
-
Haukeland University Hospital
Bergen, Norway
-
Helse Fonna HF
Haugesund, Norway
-
Helse Førde HF
Førde, Norway
-
Oslo University Hospital
Oslo, Norway
-
St.Olavs Hospital HF
Trondheim, Norway
-
Stavanger University Hospital
Stavanger, Norway
-
Universitetssykehuset Nord-Norge
Tromsø, Norway
-
Vestre Viken HF
Drammen, Norway
Conditions
Explore the condition pages connected to this study.